Home / health news / yahoo : Tokai (TKAI) Plunges after Halting Prostate Cancer Trial
alibaba.com, cpa campaign, lead generation, lead campaign, smart match lander, intelligent lander, a

yahoo : Tokai (TKAI) Plunges after Halting Prostate Cancer Trial

BioLight Reports Successful Feasibility Clinical Study Results for the Detection of Prostate Cancer with CellDetect® Non-Invasive Test

BioLight Reports Successful Feasibility Clinical Study Results for the Detection of Prostate Cancer with CellDetect® Non-Invasive Test

TEL-AVIV, Israel, July 26, 2016 /PRNewswire/ –BioLight Life Sciences Ltd. (BOLT.TA) (“BioLight” or the “Company”), an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions and also in innovations in cancer diagnostics, announced promising results from a feasibility clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect® technology.The study successfully demonstrated the feasibility of detecting intact cells originating in the prostate from urine samples following prostate massage.The CellDetect® technology is being developed by Micromedic Technologies (MCTC.TA), BioLight’s cancer diagnostics subsidiary, and allows an accurate diagnosis of cancerous and precancerous cells, based on a unique combination of color and morphology, by utilizing a proprietary kit containing unique extract and dyes.

read more from here

Tokai Pharma Shutters Prostate Cancer Drug Trial Early, Shares Crumble

Tokai Pharma Shutters Prostate Cancer Drug Trial Early, Shares Crumble

Tokai Pharma Shutters Prostate Cancer Drug Trial Early, Shares CrumbleXconomy Boston —Tokai Pharmaceuticals has been trying to play catch-up for years in the fast-moving field of prostate cancer treatments.But that plan just took a major hit this morning.Cambridge, MA-based Tokai (NASDAQ: TKAI) said that an independent data monitoring committee instructed the company to stop the big Phase 3 trial of its prospective prostate cancer drug, galeterone, early because the study was likely to fail: Galeterone wasn’t going to do better than enzalutamide (Xtandi) at stopping patients’ prostate cancer from spreading.

read more from here

‘Cyberknife’ Radiation Speeds Treatment for Prostate Cancer

'Cyberknife' Radiation Speeds Treatment for Prostate Cancer

A targeted form of radiotherapy may prove a game changer in the way that some men with prostate cancer are treated, a top expert says.Stereotactic body radiation, or SBRT, similar to the targeted radiotherapy of Cyberknife and Gamma Knife that revolutionized the treatment of brain cancer, could provide the much needed option for men with localized prostate cancer, Dr. Raquibul Hannan tells Newsmax Health.“SBRT can change the treatment paradigm of localized prostate cancer by offering men a convenient alternative to the long nine-week course of daily radiation therapy that is the current standard of care.

read more from here

Tokai (TKAI) Plunges after Halting Prostate Cancer Trial

Tokai (TKAI) Plunges after Halting Prostate Cancer Trial

Tokai Pharmaceuticals Inc (NASDAQ:TKAI) is tumbling today, having already lost more than three quarters of its market value since the market open.At the time of writing, the company’s stock has fallen 76 percent – from yesterday’s closing price of $5.20 to just $1.25.More than 2.9 million shares of Tokai have already changed hands today – a substantial increase in activity when compared to the stock’s average trading volume of less than 60,000 shares per day.

read more from here

Check Also

picture.jpg

2 missing girls found safe, mother detained according to : KCRA

as informed in Two missing girls were found safe after being taken by their biological …